Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 0:02:51
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024 21:30:00
Kazia Thrpts Sp ADR (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
0,3098 -1,24 0,00 375 544
After-hours28.03.2024 23:37:48
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
0,3113 - - -1,24 0,00
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiKazia Therapeutics Ltd (ADR)
TickerKZIA
Kmenové akcie:ADR
RICKZIA.O
ISIN-
Poslední známé roční výsledky30.06.2023
Poslední známé čtvrtletní výsledky30.06.2023
Počet zaměstnanců k 30.06.2014 12
Akcie v oběhu k 30.06.2023 228 029 114
MěnaAUD
Kontaktní informace
UliceThree International Towers Level 24
MěstoSYDNEY
PSČ2000
ZeměAustralia
Kontatní osoba 
Funkce kontaktní osoby 
Telefon61 294 724 100
Fax61294760388

Business Summary: Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2023, Kazia Therapeutics Ltd (ADR) revenues increased from A$2K to A$23K. Net loss decreased 18% to A$20.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development expense - Balan decrease of 31% to A$12.6M (expense), Loss on revaluation of contingent consid increase from A$0K to A$3.4M (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Interim Executive Chairman of the Board, Chief Executive Officer, Managing DirectorJohn Friend5211.08.202315.11.2021
Chief Financial OfficerKaren Krumeich-
Clinical & Regulatory Affairs ManagerLilischkis Kimberley-
Chief Business OfficerPeng Leong-29.08.201629.08.2016
Program Director - Degenerative DiseasesStephen Palmer-01.01.2014
Director - ATM ProgramJustine Stehn-03.02.201403.02.2014
Company SecretaryAnna Sandham-28.02.202328.02.2023